The Future of Lung Disease Interception with Ravi Kalhan, MD, MS


In addition to sharing how a novel machine learning method may one day soon predict lung disease susceptibility, Kalhan describes the science behind the ALA Lung Health Cohort Research Study.

The definition of respiratory health is relative to potential respiratory impairments and diseases, both of which researchers are continually learning more about. Take, for example, COVID-19: a relatively new and heterogeneous burden on the pulmonary system that isn’t fully defined as an acute impact yet—let alone as a chronic condition.

As such, the modeling and standard for respiratory health should be constantly changing. This month’s Lungcast feature an expert dedicated to that task.

Ravi Kalhan, MD, MS, deputy division chief of pulmonary and critical care medicine at the Northwestern Feinberg School of Medicine, joins host Albert Rizzo, MD, chief medical officer of the American Lung Association, for a discussion on the concepts and relevant research of lung disease pathophysiology, impact, and future interception strategies.

From the conceptualization of a respiratory health model, to identifying potential biomarkers through cardiovascular disease cohort data, to integrating COVID-19 outcomes research into ongoing population lung health analyses, Kalhan touches on the intricacies of his and peers’ work into truly mapping out respiratory disease.

Lungcast is a monthly respiratory health podcast series from the ALA produced by HCPLive.

Subscribe or listen to Lungcast on your favorite platforms:

Related Videos
Caroline Sisson, MMS, PA-C: Updates in Pulmonary Function Testing
© 2024 MJH Life Sciences

All rights reserved.